Sign In
Buy NNVC
$1.65
+0.140 (+9.27%)
At Close: Jul 13, 2026
SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a C
SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it
SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
09:30am, Monday, 22'nd Jun 2026
SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical T
SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides a
SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides an
SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potenti
NanoViricides closes $2M direct offering
09:08am, Tuesday, 19'th May 2026
NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses. The clinical-stage antiv
NanoViricides closes $2M direct offering
08:06am, Tuesday, 19'th May 2026
NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before...
Nasdaq semis lead losses as bond yields put pressure on Iran talks
06:00am, Tuesday, 19'th May 2026
10am: Nasdaq semiconductors lead early decline Selling dominated early trading in New York on Tuesday, with tech stocks in the firing line. The Dow Jones...
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
11:55pm, Monday, 18'th May 2026
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectru
Cyclical stocks' strong run may be due a pause despite leading markets this year, leading bank warns
11:03am, Monday, 18'th May 2026
Cyclical stocks, value shares and small caps have led European and US markets so far this year in a pattern that has surprised many investors, but JP...
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak
08:37am, Monday, 18'th May 2026
NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain of Ebola virus that has prompted the World Health
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
08:30am, Monday, 18'th May 2026
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the c
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak
04:34am, Monday, 18'th May 2026
NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain of...
